Ranking & Metrics Conference Call for Papers Other Conferences in United States
San Antonio Breast Cancer Symposium

San Antonio Breast Cancer Symposium

San Antonio , United States

Submission Deadline: Friday 15 Jul 2022

Conference Dates: Dec 06, 2022 - Dec 10, 2022

Impact Score 6.40


Conference Organizers: Deadline extended?
Click here to edit

Ranking & Metrics Impact Score is a novel metric devised to rank conferences based on the number of contributing the best scientists in addition to the h-index estimated from the scientific papers published by the best scientists. See more details on our methodology page.

Research Impact Score: 6.40
Contributing Best Scientists: 1189
Papers published by Best Scientists 2214
Research Ranking (Genetics and Molecular Biology) 3
Research Ranking (Immunology) 6
Research Ranking (Biology and Biochemistry) 3
Research Ranking (Medicine) 2

Conference Call for Papers

Abstract Subject Categories
The subject categories for abstract submission are listed below. You must select the most appropriate category for your abstract and insert its corresponding number in the box on the abstract form. Please be aware that the Symposium Abstract Review Committee may re-categorize your abstract if doing so is deemed appropriate.

Subject Categories List


Axillary Nodes
101. Axillary Staging and Sentinel Nodes
102. Diagnostic Pathology
104. Circulating Biomarkers and ctDNA
105. Circulating Tumor Cells
106. Micrometastases

Imaging and Screening
107. Breast Imaging - Mammography etc.
110. Molecular, Functional, and Novel Imaging
111. Radiology - Tumor Monitoring
112. Screening

113. Detection/Diagnosis - Other

202. Animal Models
203. Ex vivo Models
205. Cell Cycle Regulation
206. Cellular Mechanisms
207. DNA Damage and Repair
208. Drug Resistance
209. Endocrine Therapy and Resistance
210. Epigenetics
211. Epithelial-Mesenchymal Transition
212. Etiology/Carcinogenesis
213. Gene Therapy
214. Genetics - Germline Changes
215. Genetics - Somatic Changes
216. Genomics
217. Growth Factors
218. Hormonal Factors and Receptors
219. Immunology and Preclinical Immunotherapy
220. Mammary Development and Differentiation
221. Metabolism and Breast Cancer
222. Microenvironment; Stromal - Epithelial Interactions
223. MicroRNAs and Other Non-coding RNAs
224. Molecular Profiles
225. New Drugs and Mechanisms
226. Novel/Emerging Therapeutic Targets
227. Oncogenes/Tumor Suppressor Genes
228. Signaling Pathways
229. Stem/Progenitor Cells
232. Tumor Heterogeneity/Molecular Subclassification
233. Tumor Progression, Invasion, and Metastasis
235. Tumor Cell and Molecular Biology - Other


Biomarkers Predicting Treatment Response
301. Predictive Biomarkers for Chemotherapies
302. Predictive Biomarkers for Endocrine Therapies
303. Predictive Biomarkers for Targeted Therapies
304. Predictive Biomarkers for Combined Modality Therapies
305. Predictive Biomarkers – Other
Prognosis – Biomarkers of Natural History
306. Prognostic Factors - Clinical Testing and Validation
307. Prognostic Factors - Index Scores
308. Prognostic Factors - Other

401. Epidemiology - Population Studies
402. Epidemiology - Genetic and Molecular
403. Ethnic/Racial Aspects
404. Familial Breast Cancer; Genetic Testing
406. Prevention - Behavioral Interventions
407. Prevention - Nutritional Studies
408. Prevention - Clinical Trials
409. Prevention - Preclinical Studies and Model Systems
410. Risk Factors and Modeling
411. Epidemiology, Risk, and Prevention - Other


Social and Education Issues
501. Advocacy
502. Cost-Effectiveness
503. Disparities and Barriers to Care
504. Doctor-Patient Communication
505. Education

Quality of Life Issues
506. Palliation and Pain Management
507. Psychosocial Aspects
508. Quality of Life - Supportive Care
509. Survivorship Research

510. Psychosocial, QOL, and Educational Aspects - Other


Adjuvant Therapy
601. Adjuvant Chemotherapy
602. Adjuvant Endocrine Therapy
603. Adjuvant Therapy - Targeted
604. Adjuvant Therapy - Other

Advanced Disease Treatment
605. Advanced Chemotherapy
606. Advanced Endocrine Therapy
607. Advanced Therapy - Targeted
608. Advanced Therapy - Other

Surgery and Radiotherapy
609. Breast Conservation
610. Radiotherapy
611. Surgery
612. Reconstruction

Therapeutic Strategies
613. Neoadjuvant Chemotherapy
614. Neoadjuvant Endocrine Therapy
616. Antiangiogenic Therapy (Adjuvant and Metastatic)
619. HER2-Targeted Therapy
620. Immunotherapy (Clinical)
621. New Drugs and Treatment Strategies
622. Novel Targets and Targeted Agents
624. Toxicities - Management

Types and Sites of Breast Cancer
625. Bone Metastases
626. Brain Metastases
628. Male Breast Cancer
629. Inflammatory Breast Cancer

Research Resources
630. Patient Resources
631. Tissue and Data Banks
632. Clinical Trials Design and Management

633. Treatment - Other

701. Ongoing Clinical Trials (see rules below)

This category is for work that is ongoing. It is to inform and inspire, and/or to invite the collaboration of others. It is to not to discuss the trial results, either preliminary or formally completed - presentations with this type of information should be submitted as regular abstracts.

Trials with any type of focus may be submitted (treatment, prevention, biomarker endpoints, supportive care, educational, and psychosocial endpoints).

Previous Editions

2021 SABCS - San Antonio Breast Cancer Symposium

Dec 07, 2021 - Dec 10, 2021

San Antonio, Texas , United States, United States

Something went wrong. Please try again later.